Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5797843 | 0.87 | TSHR (0.54) | TSHRLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4054011 | 0.85 | LMNA (0.51) | TSHRLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4046751 | 0.83 | DAO (0.52) | TSHRLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29125694 | 0.83 | RAB9A (0.51) | TSHRLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12474423 | 0.78 | DAO (0.73) | TSHRLMNARAB9ANPC1DAO | |
| SCHEMBL29125771 | 0.75 | KMT2A (0.54) | TSHRLMNANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29125948 | 0.74 | KMT2A (0.53) | TSHRLMNANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7668214 | 0.72 | TSHR (0.52) | TSHRLMNADAOALDH1A1BTK | |
| SCHEMBL24417341 | 0.72 | GLA (0.55) | TSHRLMNAALDH1A1GLAKMT2A | |
| SCHEMBL29125953 | 0.72 | TSHR (0.54) | TSHRLMNAALDH1A1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117247361-A | Phenol-oxazolone/thioketone compound and synthetic method and application thereof | 吉首大学 | 2023-12-19 | — | — | CN | disclosed |
| US-20090299066-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ERIKSSON ANDERS | 2009-12-03 | — | — | US | disclosed |
| EP-1732903-B1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070219217-A1 | Triazolone Derivatives as Mmp Inhibitors for the Treatment of Asthma and Copd | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219217-A1 | Triazolone Derivatives as Mmp Inhibitors for the Treatment of Asthma and Copd | MMP9, MMP3, MMP25 | TSHR 1214/4885LMNA 528/4885RAB9A 2099/4885 |
| US-20090299066-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | MMP3, MMP9, MMP25 | TSHR 1155/4885LMNA 568/4885RAB9A 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.